


De Novo Designed Antimicrobial Capsids

2018/12/22 Takuya Fujiwara



Contents

1. Introduction

- the structure and function of capsids

2. Main topic: “Antimicrobial peptide capsids of de novo design”

Emiliana. D. S.; Hasan. A.; Baptiste. L.; Nilofar. F.; Angelo. B.;
James. E. N.; Nicola. M.; Santanu. R.; Jonathan. R. B.; Alexander. R.
Y.; Bart. W. H.; Maxim. G. R. *Nat. Commun.* 2017, 8(1), 2263.

3. Future perspective: My proposal

Contents

1. Introduction


- the structure and function of capsids

2. Main topic: “Antimicrobial peptide capsids of de novo design”

Emiliana. D. S.; Hasan. A.; Baptiste. L.; Nilofar. F.; Angelo. B.;
James. E. N.; Nicola. M.; Santanu. R.; Jonathan. R. B.; Alexander. R.
Y.; Bart. W. H.; Maxim. G. R. *Nat. Commun.* 2017, 8(1), 2263.


3. Future perspective: My proposal

Multiplication of Virus



**Viruses cannot multiply by themselves
Instead, viruses have the host cells replicate their genomes**

What is Capsids?




Capsids:

- enclose and shield the virus genome (DNA or RNA)
- consist of several oligomeric subunits made of protein
- Icosahedral structures are most common

Icosahedral Structure of Capsids (1)

Icosahedron consists of 20 triangular faces and 12 fivefold vertexes
Each triangle is subdivided into three proteins

Therefore, the simplest capsid would be made up by a total of
(20x3 =) 60 proteins → $T = 1$ capsid




(each arrow represents one protein)


Icosahedral Structure of Capsids (2)

How many proteins compose each face is reflected in Triangulation number T


Each capsid is divided into $20T$ triangle (shown in black)
(**Red triangle** is one face of icosahedron)



$T = 1$



$T = 3$



$T = 4$

Feasible triangulation number T is found in a simple equation:


$$T = k^2 + k \times h + h^2$$

Where k and h are any integers with no common factor

Icosahedral Structure of Capsids (3)

Capsids have structural plasticity:

- The size variations are reflected in different T numbers and these conformations are in equilibrium (example of cowpea chlorotic mottle virus is shown below)



Contents

1. Introduction

- the structure and function of capsids

2. Main topic: “Antimicrobial peptide capsids of de novo design”

**Emiliana. D. S.; Hasan. A.; Baptiste. L.; Nilofar. F.; Angelo. B.;
James. E. N.; Nicola. M.; Santanu. R.; Jonathan. R. B.; Alexander. R.
Y.; Bart. W. H.; Maxim. G. R. *Nat. Commun.* 2017, 8(1), 2263.**


3. Future perspective: My proposal

Antimicrobial Drug Strategy

Conventional approach:

“targeting intercellular processes” strategy


- rapidly acquired resistance
- impermeable bacterial membranes
- resistance of quiescent bacteria



erythromycin:
bind to 50S ribosomal subunit

“disrupting membrane” strategy

- side effect to mammalian membrane (off-target)
- necessity of locally high concentration



gramicidin A:
form an ion channel on microbial membrane


Author's Strategy

“disrupting membrane” strategy

- side effect to mammalian membrane (off-target)
- necessity of locally high concentration

+

Capsid itself is non-toxic to mammalian cells
Capsid conformations are in equilibrium



Inactive assembled state


- exist in oligomerized structure
- formed on the zwitterionic mammalian membranes

Active discrete state


- exist in α -helical structure
- formed on the anionic microbial membranes

Design of Capsids (1)

In natural viral capsids, several different proteins interface via precisely matched interactions, which is difficult to emulate



The single protein motif is designed:
one protein corresponds to one triangular face



Design of Capsids (2)

Two subunit arrangements within a triangle are possible:
“Starburst” or “Honeycomb”



Starburst

- propagate 5 or 6-fold at its termini
- tight packing


→ suitable

Honeycomb

- propagate 2-fold at its termini
- hollow vertices

→ unsuitable

Design of Capsids (3)



a triskelial hub

C₁ (+) strand
(antimicrobial without C₁ (-) strand)
C₁ (-) strand


C₃-subunit

= three C₁ (+) strand conjugating onto a triskelial hub
+ three C₁ (-) strand



triskelion

Design of Capsids (4)




Inactive assembled state
(C₁ (+) strand + C₁ (-) strand)

- coiled-coil formation
(3.5 residues per turn)
- stable in neutral condition


Active discrete state
(C₁ (+) strand) (C₁ (-) strand)

- α -helical structure
(3.6 residues per turn)
- bind to anionic microbial membrane


Amino Acid Sequence



Inactive assembled state
coiled-coil formation




Active discrete state
 α -helical structure



An Overview of C₃-subunit

Components of triangular C₃-subunit



gabcdefgabcdefgabcdef


C₁ (+) strand

KIAKLKQKIQKLKAKIAKLKQ

C₁ (-) strand



ac-βA**E**ISALE**Q**E**I**ASLE**Q**E**I**SALE**Q**

C₃ (+) strand




C₃-subunit = C₃ (+) strand + three C₁ (-) strand

Behavior of the Designed Capsids (1)




→ C₁ (+) strand and C₁ (-) strand interact along with structural change

Behavior of the Designed Capsids (2)



→ regulated properly depending on the condition (mammalian/microbial)



Structure of the Designed Capsids (1)




→ $T = 4$ capsids are major
($T = 3$ capsids cannot be formed by only equilateral triangles)

Structure of the Designed Capsids (2)

model of $T = 4$ capsid assembled from C_3 -subunit




around 5-fold vertex



around 6-fold vertex


Structure of the Designed Capsids (3)

representative cryo-electron tomography for an assembled capsid




20 nm

↓ 3D rendering



3D structure of the designed capsid
assembled into spherical, hollow shells



HIV (EMDB 1155)

Antimicrobial Activity

Cell	Peptide ^a		Cecropin B	Daptomycin	Polymyxin B	Gramicidin S
	C ₃ (+) strand	C ₃ -capsid				
Minimum inhibitory concentrations, μM^b						
<i>P. aeruginosa</i> (ATCC27853)	3	12	<2	>100	<1	>40
<i>S. aureus</i> (ATCC6538)	50	>100	>100	<8	<50	<20
<i>E. coli</i> (K12)	1.5	3	<1	>100	<1	<20
<i>B. subtilis</i> (ATCC6633)	1.5	3	>50	<8	1.5	>40
<i>S. enterica</i> (ATCC700720)	3	3	3	>50	<1	<10
<i>E. faecalis</i> (OG1X)	50	>50	<25	>100	>100	ND
<i>K. pneumoniae</i> (NCTC 5055)	>12	<25	<1	>50	<1	ND
Human erythrocytes	(LC ₅₀), μM^c >250 ^d	>250	>250	>250 ^d	UD	>20

All tests were done in triplicates
 UD undetectable, ND not determined
^aC₁ (-) strand was inactive (>250 μM)

^bTotal peptide concentration
^cMedian (50%) cell death compared to untreated cells
^dHaemolysis of <10% observed at higher concentrations

antimicrobial activity was observed

- MIC of C₃-capsid is a total concentration of individual components, so the actual active concentration is reduced to 1/4
- partial antagonistic action of C₁ (-) strand is inevitable
- weak activity toward Gram-positive bacteria is maybe due to a thicker peptidoglycan layer which induces the disassembly of the capsids

Antimicrobial Activity



Cell	Peptide ^a		Cecropin B	Daptomycin	Polymyxin B	Gramicidin S
	C ₃ (+) strand	C ₃ -capsid				
Minimum inhibitory concentrations, μM^b						
<i>P. aeruginosa</i> (ATCC27853)	3	12	<2	>100	<1	>40
<i>S. aureus</i> (ATCC6538)	50	>100	>100	<8	<50	<20
<i>E. coli</i> (K12)	1.5	3	<1	>100	<1	<20
<i>B. subtilis</i> (ATCC6633)	1.5	3	>50	<8	1.5	>40
<i>S. enterica</i> (ATCC700720)	3	3	3	>50	<1	<10
<i>E. faecalis</i> (OG1X)	50	>50	<25	>100	>100	ND
<i>K. pneumoniae</i> (NCTC 5055)	>12	<25	<1	>50	<1	ND
Human erythrocytes	(LC ₅₀), μM^c >250 ^d	>250	>250	>250 ^d	UD	>20

All tests were done in triplicates
 UD undetectable, ND not determined
^aC₁ (-) strand was inactive (>250 μM)

^bTotal peptide concentration
^cMedian (50%) cell death compared to untreated cells
^dHaemolysis of <10% observed at higher concentrations




**MIC assess the activities in relatively longer time scales (~24h)
 In order to assess them in shorter time scales (~minutes),
 bacterial viability assay and poration monitoring was conducted**

Bacterial Viability Assay



The capsids used at the MIC ($3\mu\text{M}$) showed rapid antimicrobial activity

Real Time Monitoring




→ Pore was formed in about one minutes

Summary

- capsids-like antimicrobial peptide is devised to overcome the weak point of “disrupting membrane” strategy: off-target and local high concentration



- Designed capsids are regulated precisely depending on the condition



- Capsids showed strong and rapid activity against Gram-negative bacteria by poreting the phospholipid membranes

Contents

1. Introduction

- the structure and function of capsids

2. Main topic: “Antimicrobial peptide capsids of de novo design”

Emiliana. D. S.; Hasan. A.; Baptiste. L.; Nilofar. F.; Angelo. B.;
James. E. N.; Nicola. M.; Santanu. R.; Jonathan. R. B.; Alexander. R.
Y.; Bart. W. H.; Maxim. G. R. *Nat. Commun.* 2017, 8(1), 2263.

3. Future perspective: My proposal

Future Perspective

- for more potent activity


- the designed capsids showed antimicrobial activity without cytotoxicity, but its antimicrobial activity is not strong enough to be compatible with other antimicrobial peptides



develop new antimicrobial capsids based on the peptide which have potent antimicrobial activity with strong cytotoxicity



potent antimicrobial activity
with strong cytotoxicity



weakened cytotoxicity?